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AIDS-Defining Illnesses at Initial Diagnosis of HIV in a 
Large Guatemalan Cohort
Samuel W. Reinhardt,1 Andrej Spec,2 Johanna Meléndez,3 Andrea Alonzo Cordon,3 Ian Ross,1 William G. Powderly,2 and Carlos Mejia Villatoro3,†
1Department of Medicine and 2Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri; 3Infectious Diseases Clinic, Department of Internal Medicine, 
Roosevelt Hospital, Guatemala City, Guatemala
Background. Anecdotal evidence suggests that a high proportion of patients diagnosed with HIV in Guatemala present with 
AIDS. There remain limited data on the epidemiology of AIDS-defining illnesses (ADIs) in Central America.
Methods. We conducted a retrospective cohort study of all patients living with HIV at the largest HIV clinic in Guatemala. 
Charts were analyzed for clinical and demographic data. Presence of an ADI was assessed by US Centers for Disease Control defini-
tions; patients who presented with an ADI were compared with those without ADI using descriptive statistics.
Results. Of 3686 patients living with HIV, 931 (25.3%) had an ADI at HIV diagnosis, 748 (80.3%) of whom had CD4 counts 
lower than 200 cells/mm3. Those with ADIs were more likely to be male (67.5% vs 54.6%; P < .0001) and heterosexual (89.4% vs 
85.0%; P = .005). The most common ADIs were Mycobacterium tuberculosis (55.0%), Pneumocystis jirovecii pneumonia (13.7%), 
esophageal candidiasis (13.4%), and histoplasmosis (11.4%). Histoplasmosis and HIV wasting syndrome were both more common 
among rural patients.
Conclusions. In this large Guatemalan cohort of patients currently living with HIV, a significant portion presented with an ADI. 
These data inform the most common ADIs diagnosed among survivors, show that histoplasmosis is more commonly diagnosed in 
rural patients, and suggest that HIV wasting syndrome may reflect missed histoplasmosis diagnoses.
Keywords. AIDS; AIDS-defining illnesses; global health; Guatemala; HIV. 
HIV is a significant cause of morbidity and mortality in 
Guatemala, where the disease prevalence is estimated at 0.5% of 
the adult population as of 2016 [1]. Patients with late presenta-
tion of HIV have higher morbidity and mortality than patients 
diagnosed with less advanced disease [2]. Although modern 
antiretroviral therapy (ART) was implemented in Guatemala in 
the year 2000, deaths due to HIV/AIDS have risen from 13.8 per 
100 000 in 1990 to 22.0 per 100 000 in 2012, and the percentage 
of late presenters and those with AIDS at diagnosis is high [3].
Presence of an AIDS-defining illness (ADI) at HIV diagnosis 
has been shown to increase health care costs [4]. In the United 
States and Western Europe, rates of ADIs at diagnosis range 
from 9.7% to 15.1% [2, 4–11]; the rates of ADIs tend to be higher 
in developing countries (16.1%–28.9%) [12, 13]. Anecdotally, 
the experience of HIV providers in Guatemala suggests a high 
proportion of patients present with an ADI at diagnosis, but this 
has yet to be the focus of a formal study.
Few studies of the distributions and prevalence of specific 
ADIs exist in the developing world. A  large cohort in French 
Guiana showed that the most prevalent ADIs in the post-highly 
active antiretroviral therapy (HAART) era were disseminated 
histoplasmosis, esophageal candidiasis, cerebral toxoplasmosis, 
and tuberculosis; this study also noted a decrease of HIV wast-
ing disease and a rise in histoplasmosis when improved histo-
plasmosis diagnostics were introduced into the country [14]. 
Our current study sought to identify the proportion of currently 
living patients presenting with an ADI at the time of HIV diag-
nosis in a large public hospital in Guatemala City, Guatemala, 
and to characterize the prevalence of each ADI.
METHODS
We conducted a retrospective cohort study of all patients cur-
rently living with HIV at Roosevelt Hospital in Guatemala City, 
Guatemala. Roosevelt Hospital is a large academic medical cen-
ter of 900 beds in the capital city; it is publicly funded by the 
national government, accepts no fees for services performed, 
and predominantly serves patients with limited economic 
means. The Roosevelt HIV and Infectious Diseases Clinic is 
the largest HIV clinic in the country, with a census numbering 
4128 active patients and approximately 500 new HIV diagnoses 
each year. Inclusion criteria were patients age 18 years or older 
of the Infectious Diseases Clinic at Roosevelt Hospital with a 
diagnosis of HIV who were still living during the study period 
and presented for a clinic visit. As all patients have a scheduled 
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visit every 3 months, the study period of 4 months was intended 
to capture the vast majority of the clinic census. There were 
no exclusion criteria. All patients were naïve to antiretroviral 
therapy at the time of diagnosis; similarly, no patients were on 
antifungal therapy at the time of diagnosis. The protocol was 
approved by the Roosevelt Hospital and Washington University 
in St Louis institutional review boards with waiver of consent.
Charts were accessed as patients presented for routine HIV 
clinic visits, and were examined for clinical and demographic 
data including sex, age, sexual risk category, date of diagnosis, 
region of residence in Guatemala, CD4 cell count and viral load 
at time of diagnosis, presence and type of ADI, and its site at the 
time of initial presentation. ADI presence was assessed using US 
Centers for Disease Control and Prevention (CDC) definitions 
[15]. Specific OIs were diagnosed by a combination of clinical 
presentation, imaging, and microbiology where available. Cases 
of histoplasmosis were confirmed by culture. Prior to 2013, cases 
of tuberculosis and cryptococcal meningitis were confirmed by 
culture. Starting in 2013, these cases were confirmed using myco-
bacterial nucleic acid amplification testing (GeneXpert) and 
cryptococcal antigen assays, respectively. As HIV wasting syn-
drome is considered a diagnosis of exclusion, those patients who 
carried a diagnosis of tuberculosis, histoplasmosis, Pneumocystis 
jirovecii pneumonia, Mycobacterium avium intracellulare, crypto-
sporidiosis, or isosporiasis were not considered eligible for a 
diagnosis of HIV wasting. If patients were charted as having both 
HIV wasting syndrome and one of the aforementioned, HIV 
wasting was eliminated as a diagnosis for this analysis. Patients 
were considered urban dwellers if they resided in the department 
of Guatemala, which contains Guatemala City and its immediate 
surroundings; patients from all other departments or from other 
countries were categorized as rural dwellers. Sexual risk category 
was defined by the Roosevelt HIV Clinic as either heterosexual, 
men who have sex with men (MSM), transgender, or sex worker. 
Data were also collected from patients receiving new HIV diag-
noses during the study period.
Data collection and survey implementation occurred during 
the study period, which ran from June 1, 2015, to September 
30, 2015. The on-site data collection was done using a tablet, 
which allowed staff to upload de-identified clinical data and 
survey responses directly to REDCap, a secure online applica-
tion for collecting, storing, and transmitting data from research 
studies. All transfer of information was performed through the 
secure platform provided by REDCap, which was maintained by 
Washington University, and data analysis was performed in the 
United States.
Data analysis was performed using SPSS (IBM Corp., ver-
sion 22.0). The chi-square test and the Student t test were used 
for categorical and continuous variables, respectively, to assess 
associations between clinical and demographic factors and the 
primary outcome of ADI at HIV diagnosis. The Kruskall-Wallis 
test was used to assess differences in mean CD4 and mean viral 
load at diagnosis across the 3 time categories. Statistically sig-
nificant associations were defined as P <.05.
RESULTS
A total of 3686 patients were enrolled during the study period. 
The patients were 57.9% male with a mean age of 34.4 years, and 
931 patients (25.3%) had an ADI at HIV diagnosis (Table 1). 
Except for one patient diagnosed in 1998, years of HIV diagno-
sis ranged from 2000 to 2015. Compared with patients without 
ADI at HIV diagnosis, those with ADIs were more likely to be 
male (67.5% vs 54.6%; P < .0001), more likely to report a hetero-
sexual mode of HIV acquisition (89.4% vs 85.0%; P = .005), and 
were slightly older (mean age, 35.2 years vs 34.1 years; P = .009). 
Mean HIV viral load (VL) at diagnosis was significantly higher 
in those with ADI (403 100 vs 201 100 copies/mL, P < .0001). 
Of those with ADI, 748 subjects (80.3%) had CD4 counts ≤200 
Table 1. Baseline Characteristics of 3686 Patients Living with HIV in Guatemala at Time of Presentation
ADI at Diagnosis (n = 931), 
No. (%)
No ADI at Diagnosis (n = 2755), 
No. (%) P Value
Total Cohort (n = 3686), 
No. (%)
Mean age (±SD), y 35.2 (10.3) 34.1 (11.1) .01 34.4 (10.9)
Male sex 628 (67.5) 1505 (54.6) <.0001 2133 (57.9)
Sexual risk category .005
 Heterosexual 832 (89.4) 2 342 (85.0) 3174 (86.1)
 MSM 87 (9.3) 377 (13.7) 464 (12.6)
 Transgender 3 (0.3) 15 (0.5) 18 (0.5)
 Sex worker 9 (1.0) 21 (0.8) 30 (0.8)
Mean VL at diagnosis (±SD), 1000 copies/mL 403.1 (920.0) 201.1 (517.5) <.0001 253.0 (651.7)
CD4 count at diagnosisa <.0001
 0–50 400 (43.4) 446 (16.5) 846 (23.3)
 51–100 181 (19.6) 338 (12.5) 519 (14.2)
 101–200 167 (18.1) 596 (22.0) 763 (21.0)
 201–350 112 (12.1) 687 (25.4) 799 (22.0)
 >350 62 (6.7) 639 (23.6) 701 (19.3)
Abbreviations: ADI, AIDS-defining illness; MSM, men who have sex with men; VL, viral load.
aOf the 3628 patients (922 with ADI at diagnosis, 2706 with no ADI at diagnosis) with available CD4 count at diagnosis.
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cells/mm3, while the remaining 183 (19.7%) had CD4 counts 
>200 cells/mm3.
The frequencies of individual ADIs are included in Table 2. 
The most common ADIs were Mycobacterium tuberculosis 
(55.0% of those with ADI at diagnosis, 13.9% of the entire 
HIV cohort), Pneumocystis jirovecii pneumonia (13.7%, 3.5%), 
esophageal candidiasis (13.4%, 3.4%), disseminated histoplas-
mosis (11.4%, 2.9%), toxoplasmosis (10.8%, 2.7%), extrapulmo-
nary cryptococcosis (8.7%, 2.2%), and HIV wasting syndrome 
(7.8%, 2.0%). Less common ADIs included HSV (7.5%, 1.9%) 
and CMV retinitis (2.8%, 0.7%).
The proportion of patients presenting with an ADI at time 
of HIV diagnosis was similar in urban and rural popula-
tions (P =  .382) (Table 2). However, there were differences in 
prevalence of specific ADIs. Tuberculosis was the most com-
mon ADI in both populations; however, there was a significantly 
higher rate of central nervous system toxoplasmosis among the 
urban patients (14.0% vs 9.2%; P  =  .018). Rural patients had 
higher rates of histoplasmosis (13.3% vs 7.8%; P  =  .013) and 
HIV wasting syndrome (9.2% vs 5.3%; P = .037).
Trends in the most common ADIs over time are displayed in 
Table 3. Patients were grouped by year of diagnosis (1998–2005, 
2006–2010, and 2011–2015). Overall incidence of any ADI at diag-
nosis among survivors decreased with time (P < .001). Mean CD4 
count at diagnosis significantly increased with time (P < .001); mean 
viral load at diagnosis also increased with time (P < .001), but only 
with a magnitude of 0.1 log. There were also significant increases 
over time in incidence of tuberculosis (P =  .001), histoplasmosis 
Table 2. Frequency of AIDS-Defining Illnesses Among HIV Cohort in Guatemala
AIDS-Defining Illness
 Rural Patients (n = 610), 
No. (%)
Urban Patients (n = 321), 
No. (%) P Value
Patients With ADIs 
(n = 931), No. (%)
Percentage of Entire HIV 
Cohort (n = 3686)
Any 610 (100) 321 (100) .378 931 (100) 25.2
Mycobacterium tuberculosis 339 (55.6) 173 (53.9) .662 512 (55.0) 13.9
Pneumocystis jirovecii pneumonia 85 (13.9) 43 (13.4) .835 128 (13.7) 3.5
Esophageal candidiasis 90 (14.8) 35 (10.9) .068 125 (13.4) 3.4
Histoplasmosis 81 (13.3) 25 (7.8) .013 106 (11.4) 2.9
Toxoplasmosis 56 (9.2) 45 (14.0) .018 101 (10.8) 2.7
Cryptococcosis 53 (8.7) 28 (8.7) .974 81 (8.7) 2.2
HIV wasting syndrome 56 (9.2) 17 (5.3) .037 73 (7.8) 2.0
HSV 39 (6.4) 31 (9.7) .07 70 (75) 1.9
CMV retinitis 17 (2.8) 9 (2.8) .982 26 (2.8) 0.7
Recurrent bacterial infections 17 (2.8) 5 (1.6) .243 22 (2.4) 0.6
Cryptosporidiosis 16 (2.6) 6 (1.9) .476 22 (2.4) 0.6
Primary CNS lymphoma 7 (1.1) 0 (0) .103 7 (0.8) 0.2
Other ADIa 25 (4.1) 18 (5.6) N/A 43 (4.6) 1.2
There were 0 cases of Burkitt’s lymphoma, immunoblastic lymphoma, or lymphoid interstitial pneumonia.
Abbreviations: CMV, cytomegalovirus; CNS, central nervous system; HIV, human immunodeficiency virus; HSV, herpes simplex virus.
aOther ADI includes invasive cervical cancer, recurrent pneumonia, Mycobacterium avium intracellulare, disseminated nontuberculous mycobacterium, Kaposi sarcoma, HIV encephalop-
athy, isosporiasis, CMV disease, recurrent Salmonella septicemia, disseminated coccidioidomycosis, progressive multifocal leukoencephalopathy, and pulmonary candidiasis.
Table 3. Trends of CD4 Count, Viral Load, and Most Common AIDS-Defining Illnesses Over Time
Patients With ADIs From  
1998–2005 (n = 776), No. (%)
Patients With ADIs From  
2006–2010 (n = 1654), No. (%)
Patients With ADIs From  
2011–2015 (n = 1256), No. (%) P Value
Mean CD4 count at diagnosisa (±SD) 199 (192) 188 (179) 253 (239) <.001
Mean viral load at diagnosisb (±SD), 1000 
copies/mL
217.9 (299.0) 225.0 (536.2) 309.4 (885.4) <.001
ADI at HIV diagnosis 257 (33.1) 425 (25.7) 249 (19.8) <.001
Mycobacterium tuberculosis 116 (45.1) 251 (59.0) 145 (58.2) .001
Pneumocystis jirovecii pneumonia 36 (14.0) 53 (12.5) 39 (15.7) .504
Esophageal candidiasis 45 (17.5) 49 (11.5) 31 (12.4) .074
Histoplasmosis 17 (6.6) 50 (11.8) 39 (15.7) .006
Toxoplasmosis 31 (12.1) 36 (8.5) 34 (13.7) .086
Cryptococcosis 32 (12.4) 24 (5.6) 25 (10.0) .006
HIV wasting syndrome 19 (7.4) 43 (10.1) 11 (4.4) .028
HSV 37 (14.4) 30 (7.1) 3 (1.2) <.001
CMV retinitis 8 (3.1) 12 (2.8) 6 (2.4) .89
Abbreviations: ADI, AIDS-defining illness; CMV, cytomegalovirus; HIV, human immunodeficiency virus; HSV, herpes simplex virus.
aOf the 3628 patients with available CD4 count at diagnosis.
bOf the 3113 patients with available viral load at diagnosis.
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(P = .006), decreases in HIV wasting syndrome (P = .028) and her-
pes simplex virus (P < .001), and a change over time in cryptococ-
cosis (P = .006) that was not consistently in one direction.
Data examining co-infection rates are displayed in Figure 1. 
Of the 931 patients who were diagnosed with an ADI, 622 
(66.8%) were diagnosed with a single ADI, 235 (25.2%) were 
diagnosed with 2 ADIs, 63 (6.8%) were diagnosed with 3 ADIs, 
4 (0.4%) were diagnosed with 4 ADIs, and 4 (0.4%) were diag-
nosed with 5 ADIs.
DISCUSSION
In this large cohort of living HIV patients in Guatemala, a sig-
nificant proportion (25.2%) presented with an ADI at the time 
of HIV diagnosis. The percentage of patients presenting with 
an ADI decreased over time, a trend that was also associated 
with an increase in mean CD4 at diagnosis over time. This sug-
gests that some progress has been made in diagnosing HIV ear-
lier among our population. While viral load at diagnosis also 
increased over time and reached statistical significance, this in-
crease was approximately 0.1 log, and therefore is of question-
able clinical significance. M.  tuberculosis was present in more 
than half of survivors with ADI at diagnosis, which was much 
higher than expected. Of note, many of the most common ADIs 
in our cohort of survivors, including tuberculosis and histoplas-
mosis, showed a significant increase over time. We hypothesize 
that this is due to a combination of improved diagnostics (as 
mycobacterial GeneXpert was implemented in 2013) and sur-
vival bias (as patients with these ADIs were perhaps less likely to 
survive to the study period, and ART was more readily available 
in Guatemala in the later time periods). We are unaware of any 
prior studies reporting the prevalence of ADIs among survivors 
with HIV in Central America.
In a study of ADI distribution in French Guiana, the authors 
had high suspicion that in the pre-HAART era many patients 
diagnosed with HIV wasting syndrome in fact had disseminated 
histoplasmosis that was undiagnosed. In the HAART era, which 
also corresponded with access to histoplasma antigen diagnostics 
in French Guiana, the incidence of disseminated histoplasmosis 
increased while the incidence of all other ADIs decreased [14]. 
It is possible, therefore, that a proportion of our cohort with 
HIV wasting syndrome also represented undiagnosed dissem-
inated histoplasmosis. The fact that both histoplasmosis and 
HIV wasting syndrome were significantly higher in the rural 
portion of our cohort supports this hypothesis. Improvements 
in histoplasmosis diagnostics, including the enzyme-linked 
immunosorbent assay developed by the CDC [16], as well as an 
anticipated lateral flow assay in the near future, may prove that 
histoplasmosis is a more common ADI than previously appre-
ciated in Central America. Improved diagnostics are available 
at another HIV clinic in Guatemala City, but have not been suc-
cessfully implemented at Roosevelt Hospital to date [17].
The strengths of our study include the large cohort size and 
the fact that it was performed in an area without previous data 
on ADIs at the time of HIV diagnosis. Limitations include the 
largely retrospective nature of the study (only a small per-
centage were new HIV diagnoses during the study period) 
and the fact that it is from a single center, so the conclusions 
may not be generalizable to the population of Guatemala as 
a whole. Another limitation is that data were only gathered 
from patients who were living during the study period and 
are still receiving care. This precludes any conclusions about 
the true prevalence of ADIs among HIV patients at diagnosis.
In conclusion, our study documents the significant burden of 
ADIs at the time of HIV diagnosis among survivors in a large 
Guatemalan cohort and identifies the most common ADIs diag-
nosed in this group. We show significant differences between 
rural and urban populations in terms of ADIs diagnosed and 
propose that histoplasmosis may play a larger role than cur-
rently estimated based on limited diagnostic capability.
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